dMMR – Medxy AI

Immune Checkpoint Inhibitors Deliver Durable Responses in MSI-H Gastroesophageal Adenocarcinoma

By MedXY 06/18/2026

MSI-H/dMMR gastroesophageal adenocarcinoma showed high response rates to immune checkpoint inhibitors, including durable complete responses in locoregional disease that may support carefully selected nonoperative management.

Gastroenterology news Oncology

Checkpoint Blockade Delivers Deep, Durable Responses in MSI-H Gastroesophageal Adenocarcinoma

By MedXY 06/18/2026

This single-center cohort found high and durable checkpoint inhibitor responses in dMMR/MSI-H gastroesophageal adenocarcinoma, including complete responses in locoregional disease that may support carefully selected nonoperative management.

Allergy & Immunology Oncology

More Than Half of Patients Experience Tumor Shrinkage! Clinical Data Unveiled for a Potential “First-in-Class” Therapy

By MedXY 10/24/2025

Marengo Therapeutics reports promising Phase 2 results for invikafusp alfa, showing significant tumor shrinkage and disease control in advanced solid tumors with high mutation burden or MSI-H/dMMR.

Clinical Updates news Oncology Specialties

Expanding Nonoperative Management in Mismatch Repair–Deficient Early-Stage Solid Tumors: Phase 2 Evidence for Neoadjuvant PD-1 Blockade

By MedXY 08/01/2025

Neoadjuvant PD-1 blockade with dostarlimab enabled organ preservation and high recurrence-free survival in early-stage mismatch repair–deficient (dMMR) solid tumors, extending nonoperative management beyond rectal cancer.